ArticleBMC complementary medicine and therapies2026
Therapeutic investigation of Jania rubens polysaccharides: antimicrobial activity and potentiation of chemotherapy in colorectal cancer cells.
Article in BMC complementary medicine and therapies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Chemical Profiling and In Vitro Bioactivities of Extracts from the Red AlgaMarine drugs · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSulfated polysaccharides (SPs) isolated from the marine red macroalga Jania rubens exhibit diverse biological activities. Streptococcus agalactiae (S. agalactiae) poses a particular risk to immunocompromised individuals, including cancer patients. Colorectal cancer (CRC) remains a major cause of cancer-related mortality, and resistance to chemotherapeutics such as doxorubicin (DOX) continues to limit treatment outcomes. This study investigated the antibacterial activity of Lebanese J. rubens SPs against S. agalactiae and evaluated their potential to enhance the efficacy of vancomycin and doxorubicin in human colorectal cancer cell lines (HCT-116, HT-29, Caco-2).
methodsAntibacterial activity was assessed using the agar well diffusion method, across extracts, tested at 50–4000 µg/mL. The Minimum Inhibitory Concentration (MIC) was determined and synergistic interactions of SPs and vancomycin were evaluated using the fractional inhibitory concentration index (FICI). Biofilm inhibition assays were conducted, and RT-PCR quantified the expression of genes involved in adhesion and immune evasion. Carbohydrate content was measured using the phenol–sulfuric acid method. Synergistic cytotoxic effects with DOX were evaluated in colorectal cancer cell lines (HCT-116, HT-29, Caco-2) using viability assays, and cytotoxicity was examined in the normal-like colon epithelial cell line NCM460D.
resultsSP extracts demonstrated strong antibacterial activity against S. agalactiae, even at lowest concentration tested, with an MIC of 0.39 µg/mL. Synergy with vancomycin was confirmed by FICI values and accompanied by significant inhibition of biofilm formation. The SP–vancomycin combination downregulated key virulence-associated genes, reducing cylE, fbsB2 and CpsG by 74.6%, 21.5%, 15.3%, respectively. Carbohydrate analysis indicated a glucose-rich composition (1.84 mg/mL). In cancer models, SPs markedly enhanced DOX cytotoxicity, lowering cell viability to 11% in HCT-116, 38% in HT-29, and 15% in Caco-2, compared with 58%, 87%, and 68% with DOX alone. Minimal cytotoxicity was observed in NCM460D cells, 96% at 50 µg/mL and 86% at 100 µg/mL.
conclusionThese findings indicate that the Lebanese Jania rubens sulfated polysaccharide extract exhibits dual in-vitro activities, demonstrating antibacterial effects against S. agalactiae and enhancing the in-vitro cytotoxic effect of doxorubicin in colorectal cancer cell lines. Further mechanistic and in-vivo studies are required to clarify these activities and better understand their underlying basis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.